Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lente insulin + regular insulin is a combination of two types of insulins used historically to manage blood glucose in diabetes mellitus. Lente insulin (also known as "insulin zinc suspension") is an intermediate-acting form derived from porcine and bovine sources, combined with zinc to prolong its action. It has an onset of 1–2 hours, peaks at 8–12 hours, and can last over 24 hours. Regular insulin is a short-acting human or animal-derived preparation with an onset of about 30 minutes and duration up to 6–8 hours. The combination was designed to provide both immediate (regular) and sustained (lente) glycemic control by mimicking basal and prandial endogenous insulin secretion patterns. Both act by binding the Insulin receptor on target tissues, promoting glucose uptake from the bloodstream into cells, thus lowering blood sugar levels. Lente insulins have been discontinued for human use in most countries due to the advent of more predictable recombinant human insulins and analogs[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lente insulin + regular insulin.